PE20142338A1 - Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf - Google Patents

Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf

Info

Publication number
PE20142338A1
PE20142338A1 PE2014001381A PE2014001381A PE20142338A1 PE 20142338 A1 PE20142338 A1 PE 20142338A1 PE 2014001381 A PE2014001381 A PE 2014001381A PE 2014001381 A PE2014001381 A PE 2014001381A PE 20142338 A1 PE20142338 A1 PE 20142338A1
Authority
PE
Peru
Prior art keywords
pyrid
phenyl
useful
raf kinase
amino
Prior art date
Application number
PE2014001381A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Carl Allgeier
Daniel L Flynn
Michael D Kaufman
Phenil J Patel
Craig Wolfangel
Original Assignee
Deciphera Pharmaceuticals Llc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47884613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20142338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Deciphera Pharmaceuticals Llc, Lilly Co Eli filed Critical Deciphera Pharmaceuticals Llc
Publication of PE20142338A1 publication Critical patent/PE20142338A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
PE2014001381A 2012-03-07 2013-03-05 Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf PE20142338A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PE20142338A1 true PE20142338A1 (es) 2015-01-10

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001381A PE20142338A1 (es) 2012-03-07 2013-03-05 Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf

Country Status (39)

Country Link
US (2) US8741911B2 (enExample)
EP (1) EP2850082B1 (enExample)
JP (1) JP2015509536A (enExample)
KR (1) KR20140129087A (enExample)
CN (1) CN104302646B (enExample)
AP (1) AP2014007899A0 (enExample)
AR (1) AR090151A1 (enExample)
AU (1) AU2013230146B2 (enExample)
BR (1) BR112014018528A8 (enExample)
CA (1) CA2863673A1 (enExample)
CL (1) CL2014002220A1 (enExample)
CO (1) CO7010837A2 (enExample)
CR (1) CR20140378A (enExample)
CY (1) CY1117846T1 (enExample)
DK (1) DK2850082T3 (enExample)
DO (1) DOP2014000200A (enExample)
EA (1) EA024824B1 (enExample)
EC (1) ECSP14017584A (enExample)
ES (1) ES2584387T3 (enExample)
HK (1) HK1202541A1 (enExample)
HR (1) HRP20160654T1 (enExample)
HU (1) HUE028095T2 (enExample)
IL (1) IL234052A (enExample)
IN (1) IN2014MN01575A (enExample)
LT (1) LT2850082T (enExample)
MA (1) MA37316B1 (enExample)
ME (1) ME02423B (enExample)
MX (1) MX2014010701A (enExample)
NZ (1) NZ627454A (enExample)
PE (1) PE20142338A1 (enExample)
PH (1) PH12014501986B1 (enExample)
PT (1) PT2850082T (enExample)
RS (1) RS54840B1 (enExample)
SG (1) SG11201404969YA (enExample)
SI (1) SI2850082T1 (enExample)
TN (1) TN2014000375A1 (enExample)
TW (1) TW201348233A (enExample)
UA (1) UA112340C2 (enExample)
WO (2) WO2013134252A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
KR20190017767A (ko) * 2016-06-10 2019-02-20 노파르티스 아게 C-raf 억제제의 치료적 용도
EP3878850A1 (en) 2016-12-22 2021-09-15 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
CN110545853A (zh) * 2017-04-28 2019-12-06 石英治疗有限公司 Raf降解偶联化合物
PH12020550786A1 (en) 2017-12-21 2021-04-12 Boehringer Ingelheim Int Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
JP7523351B2 (ja) 2018-01-31 2024-07-26 デシフェラ・ファーマシューティカルズ,エルエルシー 肥満細胞症の治療のための併用療法
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス, インコーポレイテッド 組み合わせ療法
LT3902547T (lt) 2018-12-28 2024-01-25 Deciphera Pharmaceuticals, Llc Csf1r inhibitoriai, skirti panaudoti vėžio gydymui
MX2021009396A (es) 2019-02-06 2021-09-10 Lilly Co Eli Derivados de 1 - ((2- (2,2,2-trifluoroetoxi) piridin-4-yl) metil) urea como potenciadores kcnq.
AR118119A1 (es) * 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
WO2020227020A1 (en) * 2019-05-03 2020-11-12 Kinnate Biopharma Inc. Inhibitors of raf kinases
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
PL3966206T3 (pl) 2019-05-10 2024-01-29 Deciphera Pharmaceuticals, Llc Heteroaryloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
AU2020297422B2 (en) 2019-06-17 2024-03-21 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
US11098031B1 (en) 2019-10-24 2021-08-24 Kinnate Biopharma Inc. Inhibitors of RAF kinases
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
NZ789199A (en) 2019-12-30 2025-07-25 Deciphera Pharmaceuticals Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
IL302807A (en) 2020-11-18 2023-07-01 Deciphera Pharmaceuticals Llc Gcn2 and perk kinase inhibitors and methods of use thereof
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
CN117561057A (zh) 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
CR20240233A (es) 2021-12-01 2024-07-17 Univ Vanderbilt Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
EP4441056A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099612A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TW202340208A (zh) 2021-12-01 2023-10-16 德商百靈佳殷格翰國際股份有限公司 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
WO2023099592A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
US20250145608A1 (en) 2021-12-01 2025-05-08 Boehringer Ingelheim Int'l GmbH Corp. Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
TW202337455A (zh) 2021-12-09 2023-10-01 美商迪賽孚爾製藥有限公司 Raf激酶抑制劑及其使用方法
CN119585242A (zh) 2021-12-09 2025-03-07 德西费拉制药有限责任公司 Raf激酶抑制剂及其使用方法
EP4452975A1 (en) 2021-12-23 2024-10-30 Boehringer Ingelheim International GmbH 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
TW202432115A (zh) 2022-10-26 2024-08-16 德商百靈佳殷格翰國際股份有限公司 可活化sting之雜環化合物
US20240174642A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
WO2024088991A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ras相關疾病或病症之組合療法
WO2024246099A1 (en) 2023-05-30 2024-12-05 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025210041A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Bicyclic benzylamido pyridine derivatives as sos1 inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
AU2003280599A1 (en) * 2002-10-29 2004-05-25 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
AR080151A1 (es) * 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Also Published As

Publication number Publication date
MX2014010701A (es) 2015-03-10
NZ627454A (en) 2016-09-30
PH12014501986A1 (en) 2014-11-24
UA112340C2 (uk) 2016-08-25
BR112014018528A8 (pt) 2017-07-11
CO7010837A2 (es) 2014-07-31
KR20140129087A (ko) 2014-11-06
BR112014018528A2 (enExample) 2017-06-20
AP2014007899A0 (en) 2014-08-31
PT2850082T (pt) 2016-07-15
PH12014501986B1 (en) 2014-11-24
EP2850082B1 (en) 2016-05-18
CN104302646A (zh) 2015-01-21
AR090151A1 (es) 2014-10-22
HUE028095T2 (en) 2016-11-28
CR20140378A (es) 2014-11-27
TN2014000375A1 (en) 2015-12-21
ES2584387T3 (es) 2016-09-27
MA37316A1 (fr) 2016-06-30
EP2850082A1 (en) 2015-03-25
CN104302646B (zh) 2016-05-04
WO2013134243A1 (en) 2013-09-12
EA024824B1 (ru) 2016-10-31
LT2850082T (lt) 2016-09-12
IL234052A (en) 2016-05-31
SG11201404969YA (en) 2014-10-30
AU2013230146B2 (en) 2015-09-10
US9334267B2 (en) 2016-05-10
JP2015509536A (ja) 2015-03-30
DK2850082T3 (en) 2016-08-15
CY1117846T1 (el) 2017-05-17
DOP2014000200A (es) 2014-10-15
US8741911B2 (en) 2014-06-03
WO2013134252A1 (en) 2013-09-12
CL2014002220A1 (es) 2015-06-05
US20130252977A1 (en) 2013-09-26
HK1202541A1 (en) 2015-10-02
AU2013230146A1 (en) 2014-08-14
RS54840B1 (sr) 2016-10-31
TW201348233A (zh) 2013-12-01
SI2850082T1 (sl) 2016-07-29
IN2014MN01575A (enExample) 2015-05-08
ECSP14017584A (es) 2016-01-29
EA201491456A1 (ru) 2014-12-30
MA37316B1 (fr) 2017-03-31
CA2863673A1 (en) 2013-09-12
US20150119392A1 (en) 2015-04-30
HRP20160654T1 (hr) 2016-07-01
ME02423B (me) 2016-09-20

Similar Documents

Publication Publication Date Title
PE20142338A1 (es) Derivados de pirido[2,3-d]pirimidina sustituidos con 2-amino, 6-fenilo utiles como inhibidores de cinasa raf
MY175450A (en) 4-amino-6-(heterocyclic)picolinates and 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their use as herbicides
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
MX368066B (es) Derivados de quinazolin-4-ona sustituida.
PH12014501488A1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
CL2015003444A1 (es) Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo
PE20170146A1 (es) Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
EA201600128A1 (ru) СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2(1Н)-ОНА, ОБЛАДАЮЩИЕ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ И АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ
MX2015000362A (es) Benzo(b)-azepin-2-onas antiproliferativas.
UA115357C2 (uk) Похідні піридин-4-ілу
MX2015007053A (es) Compuestos dimericos.
PT2864323T (pt) Derivados de 1,3-di-hidro-2h-benzimidazol-2-ona substituídos com heterociclos como agentes antivirais do vírus sincicial respiratório
PH12015500716A1 (en) N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
WO2014210319A3 (en) Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PL3013774T3 (pl) Wodny preparat zawiesinowy i jego zastosowanie jako nawozu dolistnego
AR092772A1 (es) Derivado de 7-azaindol
IN2015DN03174A (enExample)
RU2013107122A (ru) 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях
Guerra MBA Presentations July 2013 The following presentations will be held at the University Boardroom (Room 206). Monday, 7/22/2013
UA109405C2 (ru) 6-(2-r-метилселено)- 4-(2-метоксифенил)-2-оксо-1,2,3,4-тетрагидропиридин-3,5-дикарбонитрилы

Legal Events

Date Code Title Description
FD Application declared void or lapsed